Abstract
Standardized reporting of treatment response in oncology patients has traditionally relied on RECIST and PERCIST. While these endpoints are useful in prioritizing active drugs for further development, assessment of the limited number of lesions (up to 5) prevents a comprehensive evaluation of treatment response heterogeneity that most patients experience. The central hypothesis of our study was that a more complex evaluation of all lesions improves outcome prediction.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
